19 September 2018

In Clinical Gastroenterology and Hepatology Peter Siersema and Yonne Peters, theme Tumors of the Digestive Tract, showed that patients with stable persistence of non-dysplastic Barrett’s esophagus have a low risk of malignant progression and may not benefit from routine endoscopic surveillance.

ABSTRACT

Background and aims:
The risk of esophageal adenocarcinoma (EAC) in patients with non-dysplastic Barrett's esophagus (NDBE) is low, so there is debate over the role of ongoing surveillance for patients with NDBE. It is important to identify patients at low risk for progression. We assessed cancer risk based on the subsequent number of endoscopies showing persistence of NDBE in a nationwide study in the Netherlands.
Methods:
In a population-based study, patients with a first diagnosis of NDBE were selected from the Dutch nationwide registry of histopathology. We calculated incidence rates and incidence rate ratios (IRR) for high-grade dysplasia (HGD) and EAC to determine whether the number of endoscopies negative for dysplasia and the persistence of NDBE over time associate with progression to malignancy.
Results:
We identified 12,728 patients with NDBE during 2003 and 2013. HGD or EAC developed in 436 patients (3.4%) during 64,537 person-years of follow up (median, 4.9 years). The rate of progression to HGD or EAC was 0.68 (95% CI, 0.61-0.74) per 100 person-years. In patients with 2 consecutive endoscopies showing NDBE, the rate of progression to HGD or EAC decreased to 0.55 (95% CI, 0.46-0.64) per 100 person-years (IRR 0.72; 95% CI, 0.60-0.87). Overall, the incidence of HGD or EAC decreased by 14% for each year of progression-free follow-up (IRR, 0.86; 95% CI, 0.81-0.92).
Conclusion:
In a population-based study in the Netherlands, we found patients with stable NDBE to have a low risk of progression to HGD or EAC. These findings indicate that surveillance intervals might be lengthened or even discontinued in subgroups patients with persistent NDBE
 
Publication
Incidence of Progression of Persistent Non-Dysplastic Barrett's Esophagus to Malignancy.
Peters Y, Honing J, Kievit W, Kestens C, Pestman W, Nagtegaal ID, van der Post RS, Siersema PD.

Related news items


Studying the function of liver cancer genes in mini-organs

24 May 2019

Michiel Vermeulen, theme Cancer developement and immune defense, and colleagues, have developed a human model in which they use organoids, or mini organs, to study the function of specific genes that are mutated in liver cancer. Their results were published in the scientific journal Cell Stem Cell.

read more

Three VIDI grants for RIMLS researchers

24 May 2019

Three researchers from RIMLS are each to receive up to 800,000 euros to develop an innovative research theme and to build up their own research group. NWO (The Netherlands Organisation for Scientific Research) is awarding the Vidi grant as part of the Innovational Research Incentives Scheme.

read more

H2020 Grant for Frank Walboomers and Ronald Bartels

23 May 2019

Frank Walboomers and Ronald Bartels, theme Reconstructive and regenerative medicine, have received a € 500,000 grant for research into graphene biomaterials from the Europan Union Horizon 2020 FET Open programme.

read more

Innovation Grant Dutch Kidney Foundation for Jeroen de Baaij

23 May 2019

Jeroen de Baaij, theme Renal disorders, was awarded with an Innovation Grant of the Dutch Kidney Foundation. Jeroen's research proposal was selected from a competitive field of innovative approaches to treat kidney disease.

read more

Graduate school news Adjusted PhD guidelines

23 May 2019

It should be emphasized that the quality, and not the number of chapters, determines the assessment by the manuscript committee. To avoid the wrong emphasis on quantity, it is not recommended to have more than three publishable chapters in the thesis.

read more

Geraline Leusink appointed full Professor

23 May 2019

As of 1 May, Geraline Leusink has been appointed professor of 'Medicine for people with intellectual disabilities'.

read more